Experimental Treatments: Psilocybin
December 7, 2018 DOI: 10.64239/pi-vl00512 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label study |
|---|---|
| Sample size | 12 |
| Population | Patients |
| Intervention | Psilocybin |
| Duration | Up to three months |
| Topics | Psilocybin |
| Keywords | Agonist Hallucinogen Potency Pharmacology |
| Key points | Psilocybin produced rapid improvement lasting up to three months in half the group. |
Abstract
Psilocybin is a psychedelic agent with 5-HT2A agonist properties An open-label study in 12 patients showed that psilocybin produced improvement rapid improvement that lasted up to three months in half the group There are practical challenges around research and potential therapeutic use. Further research seems worthwhile.
Comparable studies
Other non-randomized and open-label trials on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression | 2016 | Open-label feasibility trial | n = 12 |
| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression | 2017 | Open-label trial | n = 20 |
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression | 2018 | Clinical trial | n = 20 |
| Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) | 2006 | Controlled clinical trial |